BeOne Medicines Ltd. - Sponsored ADR ONC
360.85
0.88
0.24%
as of 25 Sep
- Market cap
- $37.3B
- P/E
- 61.2×
Follow ONC
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
48.30 | 63.86 | 116.40 | 587.41 |
+8 more quarters Free account |
P/S ratio |
5.19 | 5.74 | 6.20 | 7.55 | |
P/FCF ratio |
24.27 | 30.10 | 35.95 | 71.58 | |
P/Operating CF |
68.70 | 163.66 | 79.39 | 93.28 | |
P/B ratio |
6.15 | 6.92 | 7.60 | 9.09 | |
Price to Tangible BV |
6.22 | 7.01 | 7.71 | 9.24 | |
EV/Sales |
4.61 | 5.19 | 5.66 | 6.91 | |
EV/EBITDA |
26.22 | 35.66 | 51.35 | 101.41 | |
EV/Operating CF |
19.05 | 23.20 | 26.82 | 43.73 | |
EV/FCF |
21.58 | 27.23 | 32.80 | 65.46 | |
Quick Ratio |
2.90 | 3.16 | 2.96 | 2.07 | |
Current Ratio |
3.41 | 3.64 | 3.41 | 2.39 | |
Net Debt/EBITDA |
(11.53) | (13.16) | (16.22) | (19.45) | |
Debt/Assets |
9.61% | 11.25% | 11.75% | 1.83% | |
Debt/Equity |
0.17 | 0.20 | 0.22 | 0.03 | |
Asset Turnover |
0.79 | 0.80 | 0.76 | 0.74 | |
Operating CF/Net income |
1.95 | 0.89 | 6.28 | 3.22 | |
Capex/Depreciation |
(0.68) | (0.99) | (1.04) | (1.29) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
35.91% | 35.76% | 41.08% | 37.08% | |
Selling, General and Administrative Expense of Revenue |
34.79% | 36.68% | 37.06% | 37.46% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
8.06% | 8.15% | 8.26% | 9.97% | |
Graham Net Nets |
0.10 | 0.09 | 0.07 | 0.06 | |
Graham Number |
78.46 | 67.00 | 48.46 | 22.11 | |
Earnings Yield |
2.07% | 1.57% | 0.86% | 0.17% | |
Free Cash Flow Yield |
4.12% | 3.32% | 2.78% | 1.40% | |
Revenue per Share |
15.28 | 13.64 | 13.74 | 12.81 | |
Operating CF per Share |
4.15 | 1.81 | 3.83 | 3.65 | |
Capex per Share |
(0.25) | (0.37) | (0.34) | (0.44) | |
Free Cash Flow per Share |
3.90 | 1.45 | 3.48 | 3.22 | |
Cash per Share |
45.69 | 43.18 | 41.70 | 36.63 | |
Shareholders Equity per Share |
46.37 | 42.90 | 39.99 | 37.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
46.37 | 42.90 | 39.99 | 37.47 | |
Free Cash Flow |
435.34 | 160.55 | 379.83 | 354.47 | |
Working Capital |
5,096.62 | 4,789.77 | 4,404.76 | 3,296.05 | |
Capital Expenditures |
(27.48) | (40.79) | (37.52) | (48.08) | |
Net Current Asset Value |
3,214.19 | 2,808.10 | 2,406.21 | 2,161.22 | |
EV/EBIT |
30.62 | 43.46 | 67.62 | 187.99 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
13.90% | 15.02% | 4.44% | 8.84% | |
Price to Operating Income |
34.44 | 48.04 | 74.10 | 205.56 | |
| Other line items | |||||
Average Receivables |
913.48 | 827.63 | 770.68 | 716.16 | |
Average Payables |
415.54 | 394.02 | 442.02 | 345.60 | |
Average Inventory |
617.74 | 588.13 | 551.61 | 481.68 | |
Average Assets |
7,737.00 | 7,197.57 | 7,054.74 | 6,731.72 | |
Average Common Equity |
4,472.24 | 4,129.98 | 3,846.71 | 3,782.70 |
Columns are period end dates